fda glp-1 enforcement news today takes aim at telehealth companies for promoting unofficial weight loss drug dupes U.S. FDA | FDA is

Among Medicare patients, 18% started with a GLP-1 while 24% used an SGLT2, reflecting the higher prevalence of cardiovascular conditions in seniors and the dual benefits SGLT2s provide in heart health

That stability lines up with recent analyst debate around Q4 results, the updated 2026 outlook, and the role of LifeMD's GLP-1 focused virtual care program in shaping long term expectations

Healthy Body Composition

FDA thresholds, insurance cutoffs, qualifying conditions, and more.

GLP-1 insurance coverage varies significantly by plan, diagnosis, and medication type

A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from the VENTURE trial published in Obesity